Active Mental Health Psychology & Behaviour

Characterising the clinical heterogeneity and aetiology of Avoidant Restrictive Food Intake Disorder

In plain English

AI plain-English summary

One in fifty children and adults cannot eat normally—not because of body image concerns, but because food itself triggers aversion, fear, or a complete lack of interest. This condition, Avoidant Restrictive Food Intake Disorder (ARFID), was only formally recognised in 2013. Clinicians still do not know whether it is a neurodevelopmental problem, an anxiety disorder, a metabolic condition, or a mix of all three. Without that basic understanding, treatment remains guesswork. Some patients end up malnourished, socially isolated, or reliant on tube feeding in hospital. The researcher will analyse large-scale cohort data to identify whether ARFID actually consists of distinct subtypes—for example, people driven by sensory sensitivity versus those driven by fear of choking or vomiting. If clear subtypes exist, each may require a fundamentally different treatment approach. This is fundamental science at an early stage. There is no immediate clinical tool or drug to deliver. But getting the diagnostic framework right now will shape every future trial, therapy, and service design. Similar foundational work on autism and ADHD transformed how those conditions are understood and treated. The same could happen here.

View original technical description
Avoidant Restrictive Food Intake Disorder (ARFID), introduced to the DSM-5 diagnostic classification system in 2013, is a severe feeding and eating disorder marked by food avoidance and restricted intake, with a prevalence of 1-2%, and serious consequences which can include malnutrition, psychosocial distress and in-patient ward tube feeding. ARFID is heterogeneous in clinical presentation, encompassing symptoms such as diminished appetite, sensory-based food aversion, and fear of adverse consequences associated with eating. This heterogeneity has raised important and related questions about the conceptualisation of ARFID. 1. Should ARFID be conceptualised as either a neurodevelopmental condition, an anxiety disorder, a consequence of metabolic imbalance or a combination of these? 2. Does ARFID consist of a collection of aetiologically distinct subtypes which will require different treatment approaches? To address this, I will use large-scale cohorts to: 1. Characterise the heterogeneity of ARFID 2. Derive data-driven subtypes 3. Investigate aetiology, and whether subtypes can be aetiologically distinguished With ARFID research in its infancy, now is the time to answer these fundamental questions to inform future aetiological research and intervention approaches. I will work with individuals living with ARFID, services, and the charity Beat, throughout the fellowship to co-produce evidence-based resources, and influence service development.

View the original record at the funder ↗

Researchers

Samuel Chawner (EPMC Awardee)

Related Research

Grants with similar aims, by meaning.

ACCESS-ED: Access to Care and Services for Eating Disorders
Understanding the role of appetite in the development of eating disorders
Developing New Clinical Pathways to Improve Outcomes for Children and Young People with Avoidant/Restrictive Food Intake Disorder
Predictors of childhood emotional under-eating.
Investigating interoceptive abilities in Eating Disorders

Original classification

Career Development Award

Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.